Postmenopausal Osteoporosis Clinical Trial
Official title:
Effect of Moringa Oleifera on Bone Density in Post-Menopausal Women
The purpose of this study is to determine the effects of Moringa Oleifera on the structure and function of bone in post-menopausal women ingesting 1000 mg of Moringa Oleifera daily for 12 weeks.
Moringa Oleifera (M. Oleifera) is a tropical plant native to northern India, Pakistan,
Himalayan regions, Africa, Central America, and Arabia that has been used for centuries in
ethnic cultures all over the world. M. Oleifera is exceptionally rich in a variety of
nutrients and medicinal phytochemicals, including those that promote bone density, such as
vitamin D, calcium, phosphorus, magnesium and others. M. Oleifera also contains
micronutrients that play a critical role in bone health and in calcium absorption, such as
boron, vitamin C, magnesium, potassium, phosphorous and others. For instance, boron
stabilizes and extends the half-life of vitamin D; magnesium (Mg) affects the activities of
osteoblasts and osteoclasts, as well as bone homeostasis by modulating the concentration of
parathormone and the activated form of vitamin D. Magnesium also contributes to bone
structural development; vitamin K reduces bone turn over, improves bone strength and plays
an essential role in osteocalcin carboxylation and vitamin C increases bone density and
strength by increasing collagen formation and promotes healing during fracture.
Collectively, these micronutrients in M. Oleifera are expected to significantly impact bone
health. Given this knowledge, the purpose of the present study is to determine the effects
of M. Oleifera on the structure and function of bone in post-menopausal women ingesting 1
gram of M. Oleifera daily for 12 weeks using DEXA scans.
The fresh young leaves of Moringa oleifera (about 2 years old) were collected by Dr. Joshua
Idassi, from a field and high tunnel plots at the North Carolina Agriculture and Technical
State University farm in July, 2014. Botanical identification and authentication were
performed by Dr. Joshua Idassi, Natural Resources Specialist, from the Cooperative Extension
Program, North Carolina A & T. A voucher specimen (LUH 2923) was deposited in the herbarium
of the University of Lagos, Akoka, Yaba, Lagos. Fresh leaves of M. Oleifera were air-dried
for about 7 days at 30 ◦C and macerated into a fine powder.
Twenty-four untrained post-menopausal women (60-70 years old) were randomly assigned to
either the control or placebo group (no program) or the experimental /treatment group (M.
Oleifera supplement group). Both groups orally ingested 1 gram (1000 mg) daily of cabbage
(placebo) or M. Oleifera (treatment group) leaf powder in capsules for 12 weeks. The bone
scans were then taken pre-supplementation and after 12 weeks to determine the effects of M.
Oleifera on various bone parameters, including bone mass density, bone mineral content, and
select anthropomorphic results including weight, body fat percentage, and lean mass
percentage.
The first visit to the laboratory by participants was utilized for providing them with
general information and as a testing session. Specifically, the information session
consisted of educating them on and obtaining signatures for informed consent, and conducting
health history and physical activity questionnaire. The first testing session consisted of
obtaining the pre-supplementation DEXA scans. The participants were then given six weeks'
worth of their supplement. The subjects came back to the testing site again at six weeks
(midway of supplementation) to pick up their supplement for the last six weeks and were then
instructed on how to fill out a three-day diet log. The diet log was analyzed and averaged
using the USDA Super Tracker online program. The third and last visit was 12 weeks after the
start of supplementation and during this visit the second set of DEXA scans were obtained
and the diet records were obtained. These records were used to determine the normal diet
nutrients as well as caffeine intake of the participants.
DEXA scanning allows for the measurement of whole body bone density, as well as the specific
density of the hip and femoral head. The subjects were laid on the DEXA machine scanner
motionless for 6-10 minutes while the scan was performed. The first scan measured total body
bone density, as well as the basic body composition. The subject were then asked to lay
motionless for another 6-10 minutes while another DEXA scan was completed, which measured
the bone density and characteristics of the hip and femoral head.The BMD, t-score and
z-scores of the whole body were recorded, as well as the BMD, t-score, and z-scores of the
right and left total hip and femoral necks. These data points were used to determine whether
there were any significant differences between the two groups after the intervention period.
The supplementation of the M. Oleifera was began after the first visit which included the
signing of the consent form, the performance of the pQCT and the DEXA scans. Once the
subjects were scanned they (subjects) were randomly assigned to either the placebo or the M.
Oleifera group. The M. Oleifera group was given the whole leaf M. Oleifera powder in capsule
form at 1000mg daily for 12 weeks and similarly the control group was given the same amount
of cabbage powder in capsule form and route. However, the placebo capsule consisting of
cabbage had significantly lower levels of vitamins and nutrients compared to M. Oleifera. M.
Oleifera was harvested and processed under optimal conditions and was carefully weighed on a
scale and packed into capsules under sterile conditions. Each capsule for both groups
contained 500 mg of the supplement, implying that each participant regardless of their
weight took two capsules daily orally for 12 weeks. If they missed a day they were
instructed not to double the dosage the next day. The placebo group was given the exact same
instructions for consumption as the M. Oleifera group, and the study was conducted in a
double blind manner. The dietary records were collected and analyzed to determine any
significant differences between the two groups based on normal daily consumed nutrients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05902078 -
Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
|
Phase 4 | |
Completed |
NCT05087030 -
Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis
|
Phase 3 | |
Completed |
NCT01544894 -
Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis
|
Phase 4 | |
Completed |
NCT00377819 -
Study of Transitioning From Alendronate to Denosumab
|
Phase 3 | |
Completed |
NCT00381251 -
Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.
|
Phase 1 | |
Completed |
NCT00239629 -
Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial
|
Phase 4 | |
Completed |
NCT04026256 -
Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
|
Phase 4 | |
Terminated |
NCT00529373 -
A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)
|
Phase 3 | |
Completed |
NCT00092014 -
A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)
|
Phase 3 | |
Recruiting |
NCT06079476 -
A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
|
Phase 4 | |
Not yet recruiting |
NCT04719650 -
Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid
|
Phase 4 | |
Recruiting |
NCT02981732 -
CLCF1 Gene Associated With Postmenopausal Osteoporosis of Kidney Yin Deficiency Syndrome
|
N/A | |
Completed |
NCT01709110 -
VERtebral Fracture Treatment Comparisons in Osteoporotic Women
|
Phase 4 | |
Completed |
NCT01348243 -
Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis
|
Phase 3 | |
Completed |
NCT00541658 -
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
|
Phase 3 | |
Completed |
NCT00395395 -
Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women
|
Phase 1 | |
Completed |
NCT00247273 -
A Study of Monthly Risedronate for Osteoporosis
|
Phase 3 | |
Active, not recruiting |
NCT03720886 -
G56W1 in Women With Postmenopausal Osteoporosis
|
Phase 1/Phase 2 | |
Completed |
NCT01668589 -
Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis
|
N/A | |
Completed |
NCT04664959 -
A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis
|
Phase 3 |